Diagonal Bio AB (publ) (NGM:DIABIO)
Sweden · Delayed Price · Currency is SEK 0.0090
0.00 (0.00%)
At close: Jul 17, 2025
Diagonal Bio AB Revenue
Diagonal Bio AB had revenue of 483.00K SEK in the quarter ending March 31, 2025, with 93.20% growth. This brings the company's revenue in the last twelve months to 1.36M, down -42.72% year-over-year. In the year 2024, Diagonal Bio AB had annual revenue of 1.13M, down -64.30%.
Revenue (ttm)
1.36M
Revenue Growth
-42.72%
P/S Ratio
9.29
Revenue / Employee
339.50K
Employees
5
Market Cap
12.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.13M | -2.03M | -64.30% |
| Dec 31, 2023 | 3.15M | -555.00K | -14.98% |
| Dec 31, 2022 | 3.71M | -4.96M | -57.25% |
| Dec 31, 2021 | 8.67M | 672.67K | 8.41% |
| Dec 31, 2020 | 8.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.31B |
| Getinge AB | 35.57B |
| Asker Healthcare Group AB | 15.57B |
| Camurus AB | 2.04B |
| Medicover AB | 23.56B |
| Vimian Group AB | 4.24B |
| AddLife AB | 10.42B |